Tony Ho, MD, Neurology, Cambridge, MA


Neurology Cambridge, MA

EVP Head of Research and Development. Crispr Therapeutics

Dr. Ho is on Doximity

As a Doximity member you'll join over a million verified healthcare professionals in a private, secure network.

  • Connect with other colleagues in the same hospital or clinic
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

See Dr. Ho's full profile

Already have an account?


  • Tony is an Oncology Vice President at Astrazeneca, currently leading the Medi-4736 (anti-PD-L1) program after he led the development and approval of Lynparza. Prior to that, Tony successfully repositioned a failed schizophrenia compound in PCOS and won the 2013 Astrazeneca Patent of the Year Award. Tony most recently co-authored two oncology review articles on oncology drug development and the use of intermediate endpoint. Prior to joining AstraZeneca, Tony was the head of Neurology and Ophthalmology at Merck and led several Phase III programs including CGRP receptor antagonist for migraine, A2a receptor antagonist for Parkinson's disease, prostaglandin for glaucoma, and several early programs in neuropathic pain, stroke, Alzheimer’s disease, and alcohol abuse. He has pioneered several novel pain trial designs and has also devised several strategies in decreasing placebo rate. He successfully filed and launched Zioptan four years earlier than initially planned and obtained Maxalt pediatric indication. The FDA praised the pediatric study design in a 2013 JAMA Pediatric review. Prior to joining Merck, Tony was the Co-Founder and Chief Scientific Officer of Neuronyx, a start-up company that developed stem cells for heart failure and immune-oncology. Tony completed his B.S. in Electrical Engineering at the University of California, Los Angeles, and received his M.D. from the Johns Hopkins University. He was Assistant Professor at Johns Hopkins Hospital specialized in neuropathy and neuromuscular diseases. Tony describing and elucidating the pathogenesis of a new disease called "acute motor axonal neuropathy (AMAN)". He has published widely in several fields with over 70 papers. He is currently Adjunct Associate Professor of Neurology at University of Pennsylvania and Assistant Professor (Part-time) of Neurology at Johns Hopkins University.

Education & Training

  • Johns Hopkins University
    Johns Hopkins UniversityResidency, Neurology, 1993 - 1996
  • Massachusetts General Hospital
    Massachusetts General HospitalResidency, Internal Medicine, 1991 - 1992
  • Johns Hopkins University School of Medicine
    Johns Hopkins University School of MedicineClass of 1991
  • University of California, Los AngelesB.S., Electrical Engineering, Summa cum Laude, 1984 - 1987

Certifications & Licensure

  • PA State Medical License
    PA State Medical License 2000 - 2022

Awards, Honors, & Recognition

  • Innovative Medicine & Early Development Science Award: Best Patent 2014
  • Global Medicines Development Team of the Year 2013
  • GHH Division Award, Inspire Integration 2011
  • Join now to see all

Publications & Presentations


Journal Articles

  • Safety and Clinical Activity of the Programmed Death-Ligand 1 Inhibitor Durvalumab in Combination With Poly (ADP-Ribose) Polymerase Inhibitor Olaparib or Vascular Endo...  
    Lee JM, Cimino-Mathews A, Peer CJ, Zimmer A, Lipkowitz S, Annunziata CM, Cao L, Harrell MI, Swisher EM, Houston N, Botesteanu DA, Taube JM, Thompson E, Ogurtsova A, Xu..., J Clin Oncol, 1/1/2017
  • Biological and clinical evidence for somatic mutations in BRCA1 and BRCA2 as predictive markers for olaparib response in high-grade serous ovarian cancers in the maint...  
    Dougherty BA, Lai Z, Hodgson DR, Orr MCM, Hawryluk M, Sun J, Yelensky R, Spencer SK, Robertson JD, Ho TW, Fielding A, Ledermann JA, Barrett JC, Oncotarget, 1/1/2017
  • Long-Term Responders on Olaparib Maintenance in High-Grade Serous Ovarian Cancer: Clinical and Molecular Characterization  
    Lheureux S, Lai Z, Dougherty BA, Runswick S, Hodgson DR, Timms KM, Lanchbury JS, Kaye S, Gourley C, Bowtell D, Kohn EC, Scott C, Matulonis U, Panzarella T, Karakasis K..., Clin Cancer Res, 1/1/2017
  • Join now to see all

Books/Book Chapters

  • Join now to see all


  • AZD 6738 ATR inhibitor 
    Santa Monica, CA - 1/18/2015
  • Tremelimumab 
    Santa Monica, CA - 1/18/2015
  • Challenges of Development of Novel Therapeutics in Ovarian Cancer 
  • Join now to see all


  • Acute Motor and Sensory Axonal Neuropathy (AMSAN) 
    Ho TW, Encyclopedia of the Neurological Sciences

Grant Support

  • Mechanism Of Injury In The Guillain Barre SyndromeNational Institute Of Neurological Disorders And Stroke1997–1999
  • Studies Of The Chinese Paralytic SyndromeNational Institute Of Neurological Disorders And Stroke1992